Posted: 12/15/2024 07:19 am
In 2022, James N. Woody, the former CEO and Director, received a total compensation of $463,500 solely as a salary, with no bonuses, stock awards, or option awards included in his package.[^1] This presents a stark contrast to his predecessor's compensation structure. In 2021, Quan Anh Vu, who served as the former Chief Operating Officer (COO) and Chief Business Officer (CBO), earned a total compensation of $911,573 which comprised a modest salary of $65,000, but was substantially bolstered by option awards worth $846,573.[^2] This signals a strategic reliance on stock-based compensation to attract and retain top executive talent in 2021.
Further illustrating the emphasis on stock and option-based compensation at ATNF, Jonathan Rothbard, the Chief Scientific Officer in 2021, received a significant portion of his compensation in options and stock awards. His total compensation amounted to $1,456,239, with $923,534 from option awards and $160,671 from stock awards, in addition to his $372,034 salary.[^3] Such a remuneration package underscores the company's approach during that period to align the interests of its executives with shareholder performance, particularly in a traditionally innovation-driven sector such as pharmaceuticals.
Turning to ATNF's current financial standing, the company’s stock price recently settled at $1.93, reflecting a small daily increase of 2.6596%.[^4] The company's market cap stands at approximately $3.82 million, indicating the challenges it faces amidst a backdrop of fluctuating stock performance. Noteworthy is its significant drop from a 52-week high of $17.75 to a low of $1.16. Despite these challenges, the company maintains a price-to-earnings (P/E) ratio of 0.24, suggesting potential undervaluation given the high earnings per share (EPS) of 7.98.[^4]
180 Life Sciences' compensation evolution appears to reflect broader trends in executive remuneration, balancing between stable cash-based salaries and fluctuating equity-based incentives. These strategies might be aimed at maintaining financial agility amidst a volatile market environment. As ATNF navigates its financial future, whether this mix serves its intended purpose remains an active point of consideration, especially given its varied stock performance and executive turnover in recent years.
[^1]: [James N. Woody Compensation](https://www.sec.gov/Archives/edgar/data/1690080/000121390024096232/0001213900-24-096232-index.htm)
[^2]: [Quan Anh Vu Compensation](https://www.sec.gov/Archives/edgar/data/1690080/000121390023042389/0001213900-23-042389-index.htm)
[^3]: [Jonathan Rothbard Compensation](https://www.sec.gov/Archives/edgar/data/1690080/000121390022022357/0001213900-22-022357-index.htm)
[^4]: [180 Life Sciences Stock Snapshot](https://www.sec.gov/Archives/edgar/data/1690080)
